Clovis Oncology Company Profile (NASDAQ:CLVS)

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Clovis Oncology, Inc. (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, May, 3rd. The company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.10. The company had revenue of $7.05 million for the quarter, compared to analyst estimates of $6.04 million. View Clovis Oncology's Earnings History.

15 brokerages have issued 1 year price targets for Clovis Oncology's stock. Their forecasts range from $23.00 to $125.00. On average, they anticipate Clovis Oncology's stock price to reach $74.54 in the next year. View Analyst Ratings for Clovis Oncology.

Here are some recent quotes from research analysts about Clovis Oncology stock:

• 1. Cann analysts commented, "We are initiating coverage of Clovis Oncology, a recently commercial-stage biotechnology company, with a Perform rating. We anticipate Clovis will continue to develop its commercial drug, Rubraca (already approved for third-line ovarian cancer), in additional indications. Rubraca (rucaparib) is a PARP inhibitor for the treatment of ovarian cancer. As a therapeutic class, PARP inhibitors—including FDA-approved Lynparza (olaparib) and Zejula (niraparib)—are designed to exploit a synthetically lethal situation in tumors that lack proper DNA repair mechanisms." (6/22/2017)
• 2. Goldman Sachs Group, Inc. (The) analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
• 3. According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca. It is not only the first approved product in Clovis’ portfolio, but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ top line, going forward. Rubraca is also under review in the EU for a comparable ovarian cancer indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Meanwhile, Clovis is looking to expand Rubraca’s label into additional indication like prostrate, breast and pancreatic cancers, among others. Also, shares of Clovis outperformed the industry in the past one year. Estimates have been stable ahead of Q4 results. However, Clovis’ dependence on Rubraca alone for growth is a cause for concern." (2/8/2017)
• 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)
• 5. J P Morgan Chase & Co analysts commented, "CLVS’ 2Q report this afternoon was fairly uneventful, though the co did note that rucaparib’s full NDA dataset had been accepted for presentation at ESMO (Oct 7- 11, Copenhagen), and that ARIEL3 data (rucap in maintenance) is now expected in 4Q17 following release of a similar data set from TSRO (though CLVS has no knowledge of the event rate in ARIEL3). While we do see potential value for rucap, we think it’s hard to differentiate between the PARPs at this stage, and we are maintaining our Neutral rating." (8/9/2016)

Clovis Oncology saw a decrease in short interest in May. As of May 15th, there was short interest totalling 8,391,818 shares, a decrease of 0.2% from the April 28th total of 8,409,669 shares. Based on an average daily trading volume, of 1,820,021 shares, the short-interest ratio is presently 4.6 days.

Some companies that are related to Clovis Oncology include TESARO (TSRO), Exelixis (EXEL), BIOVERATIV INC (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), AveXis (AVXS), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO) and Radius Health (RDUS).

Clovis Oncology's management team includes the folowing people:

• M. James E. Barrett Ph.D., Independent Chairman of the Board
• Patrick J. Mahaffy, President, Chief Executive Officer, Director
• Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
• Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer
• Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
• C. Dale Hooks, Senior Vice President, Chief Commercial Officer
• Brian G. Atwood, Independent Director
• James C. Blair Ph.D., Independent Director
• Keith T. Flaherty M.D., Independent Director
• Ginger L. Graham, Independent Director

Clovis Oncology's stock is owned by a number of of retail and institutional investors. Top institutional investors include Palo Alto Investors LLC (8.70%), Vanguard Group Inc. (7.33%), State Street Corp (4.16%), FMR LLC (4.06%), Wellington Management Group LLP (2.97%) and Boxer Capital LLC (2.23%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read and Lindsey Rolfe. View Institutional Ownership Trends for Clovis Oncology.

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, Redmile Group LLC, State Street Corp, Goldman Sachs Group Inc., Blue Jay Capital Management LLC, Morgan Stanley, Jennison Associates LLC and UBS Group AG. View Insider Buying and Selling for Clovis Oncology.

Clovis Oncology's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Wellington Management Group LLP, Alliancebernstein L.P., Vanguard Group Inc., Emerald Advisers Inc. PA, Bogle Investment Management L P DE, Boxer Capital LLC and Cibc World Markets Corp. View Insider Buying and Selling for Clovis Oncology.

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Clovis Oncology stock can currently be purchased for approximately $94.46.